TY - JOUR
T1 - Potentials of cell kinetics in the management of patients with ovarian cancers
AU - Silvestrini, R.
AU - Daidone, M. G.
AU - Valentinis, B.
AU - Di Re, E.
AU - Raspagliesi, F.
AU - Scarfone, G.
AU - Ferraris, C.
AU - Bolis, G.
AU - Landoni, F.
PY - 1992
Y1 - 1992
N2 - The relevance of 3H-thymidine labeling index (3H-dt LI) on clinical outcome was evaluated on 85 patients with advanced ovarian cancers treated with carboplatin or cisplatin alone (39 cases) or cisplatin in association with doxorubicin and/or cyclophosphamide (46 cases). 3H-dT LI of the primary tumour was significantly related to the 3-year probability of survival in patients treated by monochemotherapy (low LI, 63%; high LI, 21%; P = 0.013) but not in those treated with polychemotherapy. Analysis of the relation between cell kinetics and clinical outcome as a function of treatment showed that in patients with rapidly proliferating tumours the 3-year survival was significantly higher following polychemotherapy than monochemotherapy (51 vs. 21%; P = 0.04). In patients with slowly proliferating tumours no significant difference in survival was observed following the two types of treatment for the overall series, whereas in patients not achieving a complete response survival was significantly higher following monochemotherapy than polychemotherapy (61 vs. 9%; P = 0.008).
AB - The relevance of 3H-thymidine labeling index (3H-dt LI) on clinical outcome was evaluated on 85 patients with advanced ovarian cancers treated with carboplatin or cisplatin alone (39 cases) or cisplatin in association with doxorubicin and/or cyclophosphamide (46 cases). 3H-dT LI of the primary tumour was significantly related to the 3-year probability of survival in patients treated by monochemotherapy (low LI, 63%; high LI, 21%; P = 0.013) but not in those treated with polychemotherapy. Analysis of the relation between cell kinetics and clinical outcome as a function of treatment showed that in patients with rapidly proliferating tumours the 3-year survival was significantly higher following polychemotherapy than monochemotherapy (51 vs. 21%; P = 0.04). In patients with slowly proliferating tumours no significant difference in survival was observed following the two types of treatment for the overall series, whereas in patients not achieving a complete response survival was significantly higher following monochemotherapy than polychemotherapy (61 vs. 9%; P = 0.008).
UR - http://www.scopus.com/inward/record.url?scp=0026507188&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0026507188&partnerID=8YFLogxK
U2 - 10.1016/S0959-8049(05)80059-0
DO - 10.1016/S0959-8049(05)80059-0
M3 - Article
C2 - 1591051
AN - SCOPUS:0026507188
VL - 28
SP - 386
EP - 390
JO - European Journal of Cancer
JF - European Journal of Cancer
SN - 0959-8049
IS - 2-3
ER -